http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 Jan 2026 12:41:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/Press+Releases/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..benuru" idsrc="xmltag.org" >BENGALURU, India</location></span>, <span class="legendSpanClass"><chron>Jan. 20, 2026</chron></span> /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing <span value="Bombay:539268" idsrc="xmltag.org" >Syngene's</span> position as a http://www.streetinsider.com/PRNewswire/Syngene+International+extends+long-term+research+collaboration+with+Bristol+Myers+Squibb+until+2035/25867163.html Tue, 20 Jan 2026 12:41:00 -0500 532523 539268 539268 O.01260902 O.01268408 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Press+Releases/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767 http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html <p align="justify">BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- <b>Biocon Biologics Ltd. (BBL)</b>, a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.</p> <p align="justify"><b>Oncology Portfolio</b><br/>The company is set http://www.streetinsider.com/Globe+Newswire/Biocon+Biologics+to+Expand+Biosimilar+Oncology+Portfolio%2C+Outline+Strategic+Vision+at+the++2026+J.P.+Morgan+Healthcare+Conference/25809368.html Tue, 06 Jan 2026 07:26:00 -0500 532523 A.06930727 A.25841868 A.60012008 BIOCON.BO BIOCON.NS O.01260902 O.26741422 O.49327767